Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Isolation of heart field specific cardiomyocytes provides a platform for safe cardiac regenerative therapy

ABSTRACT: Isolation of heart field specific cardiomyocytes provides a platform for safe cardiac regenerative therapy

PROVIDER: PRJNA531317 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8867340.fastq.gz	Fastqsanger.gz
	SRR8867341.fastq.gz	Fastqsanger.gz
	SRR8867332.fastq.gz	Fastqsanger.gz
	SRR8867333.fastq.gz	Fastqsanger.gz
	SRR8867334.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Isolation of heart field specific cardiomyocytes provides a platform for safe cardiac regenerative therapy

Project description:Single-cell analysis of first and second heart field-like cardiomyocytes from differentiating hESCs.

2021-12-31 | GSE129435 | GEO

Therapeutic globin expression in thalassemia patient induced pluripotent stem cells from genomic safe harbors

Project description:The advent of human induced pluripotent stem (iPS) cells enables for the first time the derivation of unlimited numbers of patient-specific stem cells and holds great promise for regenerative medicine. However, realizing the full potential of iPS cells requires robust, precise and safe strategies for their genetic modification. Safe human iPS cell engineering is especially needed for therapeutic applications, as stem cell-based therapies that rely on randomly integrated transgenes pose oncogenic risks. Here we describe a strategy to genetically modify iPS cells from patients with beta-thalassemia in a potentially clinically relevant manner. Our approach is based on the identification and selection of âsafe harborâ sites for transgene expression in the human genome. We show that thalassemia patient iPS cell clones harboring a transgene can be isolated and screened according to chromosomal position. We next demonstrate that iPS cell clones that meet our âsafe harborâ criteria resist silencing and allow for therapeutic levels of beta-globin expression upon erythroid differentiation without perturbation of neighboring gene expression. Combined bioinformatics and functional analyses thus provide a robust and dependable approach for achieving desirable levels of transgene expression from selected chromosomal loci. This approach may be broadly applicable to introducing therapeutic or suicide genes into patient specific iPS cells for use in cell therapy. iPS cell clones were derived from beta-thalassemia patients. A single copy of beta-globin transgene cis-linked to locus control region (LCR) elements and an excisable Neo-eGFP transcription unit were inserted into these cell clones. beta-globin expression was induced by erythroid differentiation.

2010-10-26 | E-GEOD-24901 | biostudies-arrayexpress

AFBI / PATH-SAFE Salmonella

Project description:AFBI / PATH-SAFE Salmonella

| PRJEB87372 | ENA

RBM22 CUT&Tag Profiling of Regenerative (P1) and Non-Regenerative (P8) Neonatal Mouse Cardiomyocytes

Project description:Purpose: To uncover the molecular mechanisms underlying RBM22-mediated neonatal heart regeneration, we performed Cleavage Under Targets and Tagmentation (CUT&Tag) analysis on regenerative and non-regenerative wild-type (WT) mouse cardiomyocytes over a 7-day period. Methods: Cardiomyocytes were isolated from postnatal day 1 (P1, regenerative) and postnatal day 8 (P8, non-regenerative) mice, and cultured in DMEM supplemented with 10% fetal bovine serum at 37°C in a 5% CO₂ atmosphere. Cells were stained to confirm the expression of cTnT, and only those with purity >97.5% were used for subsequent experiments.Results: We carried out a CUT&Tag assay using antibody against RBM22 and found the global influence of RBM22 in regulating genes in transcription regulatory regions of key genes involved in proliferative cardiomyocyte effector function.

2026-02-12 | GSE295697 | GEO

Cyclical macrophage plasticity provides periodic inflammatory and regenerative gene expression programs in cell cycle.

Project description:Cyclical macrophage plasticity provides periodic inflammatory and regenerative gene expression programs in cell cycle.

| PRJNA739496 | ENA

RBM22 CUT&Tag Profiling of Regenerative (P1) and Non-Regenerative (P8) Neonatal Mouse Cardiomyocytes

Project description:RBM22 CUT&Tag Profiling of Regenerative (P1) and Non-Regenerative (P8) Neonatal Mouse Cardiomyocytes

| PRJNA1255616 | ENA

Therapeutic globin expression in thalassemia patient induced pluripotent stem cells from genomic safe harbors

Project description:The advent of human induced pluripotent stem (iPS) cells enables for the first time the derivation of unlimited numbers of patient-specific stem cells and holds great promise for regenerative medicine. However, realizing the full potential of iPS cells requires robust, precise and safe strategies for their genetic modification. Safe human iPS cell engineering is especially needed for therapeutic applications, as stem cell-based therapies that rely on randomly integrated transgenes pose oncogenic risks. Here we describe a strategy to genetically modify iPS cells from patients with beta-thalassemia in a potentially clinically relevant manner. Our approach is based on the identification and selection of “safe harbor” sites for transgene expression in the human genome. We show that thalassemia patient iPS cell clones harboring a transgene can be isolated and screened according to chromosomal position. We next demonstrate that iPS cell clones that meet our “safe harbor” criteria resist silencing and allow for therapeutic levels of beta-globin expression upon erythroid differentiation without perturbation of neighboring gene expression. Combined bioinformatics and functional analyses thus provide a robust and dependable approach for achieving desirable levels of transgene expression from selected chromosomal loci. This approach may be broadly applicable to introducing therapeutic or suicide genes into patient specific iPS cells for use in cell therapy.

2010-10-26 | GSE24901 | GEO

Quantitative proteomics after spinal cord injury in a regenerative and a non-regenerative stage in Xenopus laevis

Project description:The capacity to regenerate the spinal cord after an injury is a coveted trait that only a limited group of non-mammalian organisms can achieve. In Xenopus laevis, this capacity is only present during larval or tadpole stages, but is absent during postmetamorphic frog stages. This provides an excellent model for comparative studies between a regenerative and a non-regenerative stage to identify the cellular and molecular mechanisms that explain the difference in regenerative potential. Here, we used iTRAQ chemistry to obtain a quantitative proteome of the spinal cord 1 day after a transection injury, and used sham operated animals as controls. We quantified a total of 6,384 proteins, with 172 showing significant differential expression in the regenerative stage and 240 in the non-regenerative stage, with an overlap of only 14 proteins. Functional enrichment analysis revealed that while the regenerative stage downregulated synapse/vesicle and mitochondrial proteins, the non-regenerative stage upregulated lipid metabolism proteins, and downregulated ribosomal and translation control proteins. Furthermore, STRING network analysis showed that proteins belonging to these groups are highly interconnected, providing interesting candidates for future functional studies.

2018-01-25 | PXD006993 | Pride

Cyclical macrophage plasticity provides periodic inflammatory and regenerative gene expression programs in cell cycle [scRNA-seq]

Project description:Cyclical macrophage plasticity provides periodic inflammatory and regenerative gene expression programs in cell cycle [scRNA-seq]

| PRJNA739501 | ENA

Cyclical macrophage plasticity provides periodic inflammatory and regenerative gene expression programs in cell cycle [ChIP-seq]

Project description:Cyclical macrophage plasticity provides periodic inflammatory and regenerative gene expression programs in cell cycle [ChIP-seq]

| PRJNA739498 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data